David Holtzman is Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology, as well as Scientific Director at Hope Center for Neurological Disorders, Washington University School of Medicine. He is also the associate director of the Knight ADRC and co-founded the company C2N Diagnostics in 2007.

In addition to his laboratory, administrative and teaching duties, David Holtzman is involved in clinical and research activities at the Washington University Memory and Aging Project and the Alzheimer’s Disease Research Center. Holtzman has carried out ground-breaking studies of molecules involved in beta-amyloid (Aβ) metabolism (such as apoE) and the initiation of Alzheimer’s pathology and the role of vascular factors such as amyloid angiopathy in the disease. He also has contributed greatly to our understanding of how anti-amyloid antibodies affect Alzheimer’s pathology and how Aβ is cleared from the brain of Alzheimer’s disease patients.

David Holtzman received his BS and MD from Northwestern University followed by a Neurology residency at UCSF from 1985-1989. He did post-doctoral research at UCSF. There, in addition to his research, he founded a Memory Disorders clinic.